Raasi + SGLT2I + GLP1-RA
Intervention1 paper2 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
- Humans1
Associations
2Major adverse kidney events
downin humans1
1 study
Major adverse kidney events
downin humans1
Raasi + SGLT2I + GLP1-RA lowers the risk of major adverse kidney events in humans (aHR 0.509, 95% CI 0.374-0.693).
Humansin patients with T2DM and CKD on RAASin = 19,139
Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 27 Aug 2026
Mortality
downin humans1
1 study
Mortality
downin humans1
Raasi + SGLT2I + GLP1-RA lowers the risk of mortality in humans (aHR 0.317, 95% CI 0.234-0.429).
Humansin patients with T2DM and CKD on RAASin = 19,139
Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 27 Aug 2026